X
40.05
0.60 (1.52%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Xenon Pharmaceuticals Inc. | 看跌 | 看跌 |
AIStockmoo 评分
0.0
| 分析师共识 | 4.0 |
| 内部交易活动 | -3.0 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.00 |
|
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Mid Core |
| 内部持股比例 | 0.38% |
| 机构持股比例 | 101.18% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 60.00 (Needham, 49.81%) | 购买 |
| 中 | 53.00 (32.34%) | |
| 低 | 50.00 (Raymond James, 24.84%) | 购买 |
| 平均值 | 54.33 (35.66%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 40.61 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Dec 2024 | 53.00 (32.33%) | 购买 | 39.45 |
| 13 Nov 2024 | 53.00 (32.33%) | 购买 | 41.97 | |
| Needham | 13 Nov 2024 | 60.00 (49.81%) | 购买 | 41.97 |
| Raymond James | 10 Oct 2024 | 50.00 (24.84%) | 购买 | 40.41 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| AULIN SHERRY | - | 39.35 | -25,334 | -996,893 |
| 累积净数量 | -25,334 | |||
| 累积净值 ($) | -996,893 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 39.35 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| AULIN SHERRY | 职员 | 18 Dec 2024 | 处理 (-) | 6,625 | 39.35 | 260,694 |
| AULIN SHERRY | 职员 | 18 Dec 2024 | 卖 (-) | 18,709 | 39.35 | 736,199 |
| AULIN SHERRY | 职员 | 18 Dec 2024 | 执行期权 | 25,334 | - | - |
| 日期 | 类型 | 细节 |
|---|---|---|
| 06 Dec 2024 | 公告 | Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 |
| 25 Nov 2024 | 公告 | Xenon to Showcase New Long-Term Azetukalner Data at AES 2024 |
| 13 Nov 2024 | 公告 | Xenon to Present at Upcoming Investor Conferences |
| 12 Nov 2024 | 公告 | Xenon Reports Q3 2024 Financial Results and Business Update |
| 05 Nov 2024 | 公告 | Xenon to Report Q3 2024 Financial Results on November 12, 2024 |
| 02 Oct 2024 | 公告 | Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合